This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Depomed Announces Serada® NDA Acceptance And FDA Advisory Committee Meeting

MENLO PARK, Calif., Oct. 15, 2012 /PRNewswire/ -- Depomed, Inc. (Nasdaq: DEPO) today announced that its New Drug Application (NDA) for Serada® has been accepted for filing by the U.S. Food and Drug Administration (FDA).  In addition, the FDA has informed the company that the FDA's Reproductive Health Drugs Advisory Committee will discuss the Serada NDA at an Advisory Committee meeting tentatively scheduled for March 4, 2013.

The NDA will be subject to a standard review and will have a Prescription Drug User Fee Act (PDUFA) action date of May 31, 2013.  The acceptance of the NDA reflects the FDA's determination that the application is sufficiently complete to permit a substantive review.  The PDUFA date is the goal date for the FDA to complete its review of the NDA.

Serada is Depomed's proprietary extended release formulation of gabapentin in development for the treatment of menopausal hot flashes.  Depomed submitted the Serada NDA to FDA on July 31, 2012.  Depomed is seeking approval to market and sell Serada in the United States for the treatment of menopausal hot flashes.  Serada is an investigational product and is not approved to treat any disease or condition.  

"Acceptance of the NDA for Serada and scheduling of an Advisory Committee are important milestones. We believe that Serada may be a viable non-hormonal product candidate for the treatment of menopausal hot flashes, based on our and numerous academic studies that have demonstrated that gabapentin may be effective in treating hot flashes," said Jim Schoeneck, President and CEO of Depomed.

About Menopausal Hot Flashes

Hot flashes affect 75% of menopausal women or 32 million women in the U.S. annually.  Hot flashes are characterized by a sudden, temporary onset of body warmth, flushing and sweating.  For those menopausal women who suffer, even small fluctuations in body temperature can cause them to experience profuse sweating or severe chills.  Hot flashes are disruptive and impact women's overall quality of life, affecting their mood and their ability to sleep.  In fact, insomnia typically worsens with the severity of hot flashes.  According to the North American Menopause Society, hot flashes are the most common menopause-related discomfort.  For some women, these symptoms can persist for 10 years or more.  The exact cause of hot flashes is not known.

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,911.86 -73.75 -0.43%
S&P 500 1,965.49 -7.34 -0.37%
NASDAQ 4,402.1230 -16.9110 -0.38%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto
Advertising Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs